ECE2013 Oral Communications Diabetes & Obesity (6 abstracts)
1Aarhus University Hospital, Aarhus, Denmark; 2Novo Nordisk A/S, Bagsværd, Denmark; 3University of Copenhagen, Copenhagen, Denmark.
Glucagon-like peptide-1 (GLP-1) is an incretine hormone with multiple actions besides control of glucose homeostasis. GLP-1 is known to cause natriuresis in humans but the effects on basic renal physiology are still partly unknown.
This study therefore aimed to demonstrate the effects of GLP-1 on kidney hemodynamics, electrolyte handling, and the reninangiotensinaldosterone system in healthy men.
Twelve healthy young males were examined in a randomized, controlled, double-blinded, single-day, cross-over trial to evaluate the effects of two hours GLP-1 infusion on kidney functions. Glomerular filtration rate (GFR) and renal plasma flow (RPF) were assessed with 51Cr-EDTA and 123I-hippuran, respectively, using a constant infusion renal clearance technique based on timed urine sampling.
GLP-1 had no significant effect on either GFR (+1.9%, 95% CI (−0.8; 4.6%)) or RPF (+2.4%, 95% CI (−3.6; 8.8%)). Fractional urine excretion of lithium increased 9% (P=0.013) and renal sodium clearance increased 40% (P=0.007). Angiotensin II decreased 19% (P=0.003) while renin, aldosterone, and the urinary excretion of angiotensinogen showed no significant changes.
The results indicate that although GLP-1 markedly reduces proximal tubule sodium reabsorption, the acute effects on GFR and RPF are very limited in healthy humans. The finding of GLP-1s ability to reduce angiotensin II concentration is novel and may play a part in the possible kidney protective properties of GLP-1.